Diabetes Self-Care Declines During Breast Cancer Treatment
Overview
A systematic review found that diabetes self-care significantly declines during adjuvant breast cancer treatment, with reduced monitoring, poorer glycemic control, and increased emotional distress. Patients often prioritize cancer treatment over diabetes management, leading to suboptimal diabetes outcomes and challenges in concurrent care.
Background
Managing diabetes during breast cancer treatment presents unique challenges as patients face treatment-related symptoms such as fatigue, nausea, and appetite loss that disrupt established diabetes routines. The dual burden of cancer and diabetes complicates self-care, with patients experiencing difficulty distinguishing symptoms and increased mental health strain. Coordination between oncology and diabetes care is often unclear, resulting in reduced diabetes monitoring and guidance. Understanding these challenges is critical to improving outcomes for patients with both conditions.
Data Highlights
Measure
Finding
Glycated Hemoglobin Testing Decline
2% greater reduction over 24 months; 5% greater decline within 6 months post-cancer diagnosis vs controls
Patients Reporting Poor Glucose Control
60% reported out-of-control glucose levels during treatment
Patients Reporting Glucose >200 mg/dL
Nearly 50%
Glycated Hemoglobin Values
Generally ranged from 7% to 8%, indicating suboptimal control
Odds of Poorer Diabetes Control with Cancer-Related PTSD
6.6 times higher
Odds of Greater Emotional Impact from Diabetes with PTSD
3.7 times higher
Key Findings
Diabetes self-care behaviors such as diet adherence, physical activity, glucose monitoring, and medication use decline during breast cancer treatment.
Glycated hemoglobin testing and monitoring decrease significantly after breast cancer diagnosis compared to controls.
High prevalence of poor glycemic control reported, with many patients experiencing glucose levels above 200 mg/dL.
Mental health burden, including cancer-related post-traumatic stress, is strongly associated with poorer perceived diabetes control and emotional distress.
Care coordination gaps exist, with uncertainty about clinician responsibility for diabetes management during cancer treatment.
Clinical Implications
Clinicians should be aware of the increased risk of diabetes self-care decline during breast cancer treatment and proactively address monitoring and management challenges. Integrating diabetes care into oncology treatment plans and providing clear guidance may improve glycemic control and reduce emotional distress. Personalized interventions, such as virtual diabetes care visits, show promise in supporting patients through concurrent management.
Conclusion
Breast cancer treatment adversely affects diabetes self-care, leading to poorer glycemic control and increased emotional burden. Improved care coordination and targeted interventions are needed to support patients managing both conditions simultaneously.
References
Murfet et al. 2024 -- Diabetes Self-Care Declines During Breast Cancer Treatment
Metabolomics analysis identified higher uric acid levels in patients with lipedema and lymphedema, although associations weakened following adjustment for renal insufficiency.
